Adlai Nortye and Erasca outperform ImmunityBio with Q4 gains

ImmunityBio (IBRX) notched its strongest quarter ever with a 287% gain, yet Adlai Nortye (ANL) rose 387% and Erasca (ERAS) gained 335%, outperforming the biotech giant. ANL advanced after dosing its first US patient, while Erasca climbed on drug rights and Phase 1 results. These smaller firms drove outsized sector returns, leaving ImmunityBio and the biotech ETF behind.